| __timestamp | BioCryst Pharmaceuticals, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 16606000 |
| Thursday, January 1, 2015 | 1896000 | 21497000 |
| Friday, January 1, 2016 | 2699000 | 25462000 |
| Sunday, January 1, 2017 | 1702000 | 28195000 |
| Monday, January 1, 2018 | 471000 | 33078000 |
| Tuesday, January 1, 2019 | 4101000 | 36523000 |
| Wednesday, January 1, 2020 | 1676000 | 41455000 |
| Friday, January 1, 2021 | 7264000 | 74400000 |
| Saturday, January 1, 2022 | 6594000 | 101582000 |
| Sunday, January 1, 2023 | 4661000 | 112903000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding cost structures is crucial. Over the past decade, Veracyte, Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue. Veracyte's cost of revenue has surged by over 580% from 2014 to 2023, reflecting its aggressive growth and expansion strategies. In contrast, BioCryst's costs have fluctuated, peaking in 2021 with a 5,855% increase from 2014, before stabilizing. This divergence highlights Veracyte's consistent upward trajectory, while BioCryst's path has been more volatile. Such insights are invaluable for investors and stakeholders aiming to navigate the biotech landscape. As we delve deeper into these trends, it becomes evident that strategic decisions and market conditions play pivotal roles in shaping a company's financial health.
Analyzing Cost of Revenue: Eli Lilly and Company and Veracyte, Inc.
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Veracyte, Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.